Summit Therapeutics Stock Sinks 7% After FDA Rejects Its Lung-Cancer Drug Application

The treatment delayed cancer progression, but the FDA found the trial insufficient to establish that its benefits outweighed its risks.

Share
Summit Therapeutics Stock Sinks 7% After FDA Rejects Its Lung-Cancer Drug Application

Summit Therapeutics, which develops cancer medicines, fell 6.8% in Monday trading after announcing Sunday that the FDA had rejected its application for ivonescimab with chemotherapy. Shares traded at $13.19 as of 9:52 a.m. ET, wiping out $768 million in market value.

Progression Benefit Fell Short

The rejection covered treatment for previously treated patients with advanced lung cancer. Summit said the FDA found the global late-stage trial insufficient to establish that the treatment's benefits outweighed its risks.

Patients experienced a delay in progression, but the trial missed its main goal of a statistically significant improvement in overall survival. That distinction sits at the center of the rejection: slowing the disease did not secure approval.

Summit submitted the application in the fourth quarter of 2025 for patients whose lung cancers have EGFR mutations. The FDA accepted it in January 2026 and set November 14, 2026, as its target decision date.

The stock was on pace for its fifth straight daily decline Monday and stood 55% below its 52-week high. Summit's market value was about $10.5 billion in Monday trading.

AstraZeneca's $2 Billion Backing

The setback followed AstraZeneca's completion of a $2 billion equity investment last month. Summit kept development rights, and the agreement included a collaboration to test a drug combination.

Summit reported a third-quarter net loss of $208.4 million. It ended the quarter with $629.8 million in cash and investments, before receiving AstraZeneca's investment.

Ivonescimab combines the blocking of PD-1 and VEGF proteins in one antibody. Summit licensed the drug from Akeso in January 2023 and holds exclusive development and sales rights across the Americas, Europe, Japan, the Middle East and Africa. Akeso retains the remaining territories, including China.

Trials Extend Beyond Lung Cancer

Summit has no approved products and is testing ivonescimab in lung, colorectal, bladder and kidney cancers. Its program includes late-stage lung-cancer studies in previously untreated patients, both with chemotherapy and as a standalone treatment, plus a late-stage colorectal-cancer trial.

The bladder-cancer study pairs ivonescimab with enfortumab vedotin. The kidney-cancer study tests multiple combinations in patients with metastatic clear cell disease.

In the company's Wednesday results release, Dr. Maky Zanganeh, Summit's president and co-chief executive, said its program was expanding through combination collaborations involving ivonescimab with Datroway® and sone-ve. The release also named collaborations with Daiichi Sankyo and Arcus.

Akeso's late-stage studies in China reported statistically significant survival benefits against pembrolizumab in PD-L1-positive advanced lung cancer and against durvalumab plus chemotherapy in biliary tract cancer. Those findings concern different treatment settings from the application the FDA rejected.

The rejection leaves Summit pursuing its broader clinical program while the previously treated lung-cancer regimen remains without FDA approval.

Sources

More on Summit Therapeutics

All Summit Therapeutics (SMMT) coverage →